CorMedix Inc. (CRMD) Stock Analysis — Probabli.AI
AI-powered analysis for CRMD (CorMedix Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $7.38 · Market cap: $583.4M · AI outlook: Bullish
CorMedix Inc. presents an exceptional growth opportunity, driven by extraordinary projected revenue growth, strong product appeal (e.g., Neutrolin), and strategic expansion efforts. Regulatory risks and trial delays are noted, but the company's fundamentals, coupled with positive analyst sentiment and a strong growth-oriented pipeline, bolster a favorable long-term investment outlook.
Probabilistic 1-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 1-year price estimates — P10: $6 / P50: $14 / P90: $19
- CorMedix Inc. has fundamentally strong growth indicators, including a massive revenue growth estimation of 24260%. Analyst consensus of a strong buy and a median price target nearly double the current price strongly…
5-Year Outlook
- Bull 75% · Neutral 20% · Bear 5%
- 5-year price estimates — P10: $12 / P50: $28 / P90: $44
SWOT Highlights
- Strength: FDA approval of Neutrolin and subsequent revenue surge.
- Strength: Strong partnerships with major biopharma companies.
- Risk: Recent delays in clinical trials and regulatory challenges.
- Risk: Dependency on the success of key product launches.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate CRMD a STRONG BUY with a mean price target of $15.2.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
CRMD forecast details · CRMD sentiment details · CRMD insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.